Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vitrakvi

- PMLiVE

Boehringer Ingelheim’s idiopathic pulmonary fibrosis treatment recommended by NICE

Patients will be eligible for the antifibrotic treatment earlier in the course of their disease

- PMLiVE

NHS England set to be first in world to eliminate hepatitis C by 2030

Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn

- PMLiVE

Bristol Myers Squibb’s Opdivo recommended by NICE for rare gastroesophageal cancers

The PD-1 inhibitor demonstrated a statistically significant benefit in overall survival

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

NHS England gives GPs direct access to cancer tests to speed up diagnosis

From November, GP teams can directly order CT scans, ultrasounds or brain MRIs

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

- PMLiVE

ICR calls for further discussions following NICE’s rejection of breast cancer drug

Olaparib has been shown to cut the risk of cancer recurrence and improve survival

- PMLiVE

Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma

The treatment showed a significant improvement in overall survival versus placebo

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

NHS England delivers over 13 million flu vaccinations as infection rate rises

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

- PMLiVE

NHS England hits ten million in autumn COVID-19 booster campaign

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

- PMLiVE

NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia

Patients with chronic ITP may live with an increased risk of severe bleeding events

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links